Is Philip Morris Stock Overvalued?
If there is one industry that can be termed truly…
Sell
50
MCK Quote, Financials, Valuation and Earnings
Last price:
$584.46
Seasonality move
:
1.18%
Day range:
$581.90 - $598.00
52-week range:
$464.42 - $637.51
Dividend yield:
0.45%
P/E ratio:
30.35x
P/S ratio:
0.23x
P/B ratio:
--
Volume:
980.6K
Avg. volume:
752.3K
1-year change:
20.94%
Market cap:
$74.4B
Revenue:
$309B
EPS (TTM):
$19.31
Analysts' Opinion
-
Consensus RatingMcKesson has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $650.81, McKesson has an estimated upside of 11.05% from its current price of $586.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $530.00 representing 9.57% downside risk from its current price of $586.08.
Fair Value
-
According to the consensus of 14 analysts, McKesson has 11.05% upside to fair value with a price target of $650.81 per share.
MCK vs. S&P 500
-
Over the past 5 trading days, McKesson has underperformed the S&P 500 by -1.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
McKesson does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
McKesson has grown year-over-year revenues for 17 quarters straight. In the most recent quarter McKesson reported revenues of $93.7B.
Earnings Growth
-
McKesson earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter McKesson reported earnings per share of $1.87.
Enterprise value:
78B
EV / Invested capital:
--
Price / LTM sales:
0.23x
EV / EBIT:
21.10x
EV / Revenue:
0.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
18.09x
Price / Operating cash flow:
17.84x
Enterprise value / EBITDA:
17.94x
Gross Profit (TTM):
$13.1B
Return On Assets:
3.69%
Net Income Margin (TTM):
0.77%
Return On Equity:
--
Return On Invested Capital:
64.32%
Operating Margin:
0.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $272B | $291.1B | $330.2B | $77.2B | $93.7B | |
| Gross Profit | $12.9B | $12.3B | $13.1B | $3.1B | $3.2B | |
| Operating Income | $3.3B | $4.5B | $3.9B | $977M | $745M | |
| EBITDA | $4B | $5.3B | $4.3B | $1.1B | $775M | |
| Diluted EPS | $14.11 | $25.31 | $19.31 | $4.92 | $1.87 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $42.3B | $45.6B | $46.4B | $47.5B | $53.3B | |
| Total Assets | $61.6B | $63.6B | $63.1B | $66.1B | $72.4B | |
| Current Liabilities | $42.7B | $46.1B | $48.4B | $51.1B | $58.8B | |
| Total Liabilities | $54.2B | $63.7B | $64.3B | $67.6B | $75.1B | |
| Total Equity | $7.4B | -$87M | -$1.2B | -$1.5B | -$2.6B | |
| Total Debt | $7.6B | $6B | $5.6B | $5.6B | $5.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.4B | $4.9B | $5.1B | $965M | $2.1B | |
| Cash From Investing | $184M | -$973M | -$1.1B | -$166M | -$286M | |
| Cash From Financing | -$4.2B | -$4.4B | -$4B | -$909M | -$1.6B | |
| Free Cash Flow | $4B | $4.3B | $4.3B | $825M | $1.9B | |
MCK
Sector
Market Cap
$74.4B
$45.7M
Price % of 52-Week High
91.93%
47.48%
Dividend Yield
0.45%
0%
Shareholder Yield
5.95%
-0.75%
1-Year Price Total Return
20.94%
-32.34%
Beta (5-Year)
0.521
0.746
Dividend yield:
0.45%
Annualized payout:
$2.40
Payout ratio:
12.89%
Growth streak:
11 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$588.51
200-day SMA
Buy
Level
$559.96
Bollinger Bands (100)
Buy
Level
506.35 - 600.27
Chaikin Money Flow
Buy
Level
356.9M
20-day SMA
Buy
Level
$581.40
Relative Strength Index (RSI14)
Buy
Level
51.22
ADX Line
Buy
Level
20.97
Williams %R
Neutral
Level
-36.9808
50-day SMA
Sell
Level
$594.94
MACD (12, 26)
Buy
Level
1.72
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
245.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6199)
Sell
CA Score
(Annual)
Level (-0.742)
Buy
Beneish M-Score
(Annual)
Level (-2.4055)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.1596)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Stock Forecast FAQ
In the current month, MCK has received 10 Buy ratings 4 Hold ratings, and 0 Sell ratings. The MCK average analyst price target in the past 3 months is $650.81.
-
Where Will McKesson Stock Be In 1 Year?
According to analysts, the consensus estimate is that McKesson share price will rise to $650.81 per share over the next 12 months.
-
What Do Analysts Say About McKesson?
Analysts are divided on their view about McKesson share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that McKesson is a Sell and believe this share price will drop from its current level to $530.00.
-
What Is McKesson's Price Target?
The price target for McKesson over the next 1-year time period is forecast to be $650.81 according to 14 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is MCK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for McKesson is a Buy. 10 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MCK?
You can purchase shares of McKesson via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase McKesson shares.
-
What Is The McKesson Share Price Today?
McKesson was last trading at $584.46 per share. This represents the most recent stock quote for McKesson. Yesterday, McKesson closed at $586.08 per share.
-
How To Buy McKesson Stock Online?
In order to purchase McKesson stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Quantum Stocks Should I Buy?
The last several years have seen a series of tech…
Will Sirius XM Be a 10-Bagger Stock?
Last year, Warren Buffett surprised practically everyone when he acquired…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
32
FTAI alert for Jan 22
FTAI Aviation [FTAI] is up 9.81% over the past day.
Sell
2
EDU alert for Jan 22
New Oriental Education & Technology Group [EDU] is down 1.13% over the past day.
Buy
51
GH alert for Jan 22
Guardant Health [GH] is up 4.5% over the past day.
